Incidence of Lung Adenocarcinoma following Recurrent Deep Vein Thrombosis: A Case Presentation

Authors

  • Ali Sharifpour Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Siavash Abedi Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Masoud Aliyali Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Sepideh Safa Navai Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
  • Ali Davoodi Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
  • Seyyed Abbas Hashemi Resident in Internal Medicine, Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari

DOI:

https://doi.org/10.6000/1927-7229.2018.07.02.3

Keywords:

Lung, Adenocarcinoma, Thrombosis.

Abstract

Deep vein thrombosis (DVT) is a common disease that can lead to death. Many studies have looked at the chance of occurrence and the factors affecting thrombosis as one of the complications of cancer. This chance increases in patients with more severe cancer. The progression of cancer and the risk of death in patients with DVT is more severe and with a worse prognosis. But according to our knowledge, there is no accurate report of the incidence and diagnosis of cancer long after thrombosis .In our case, lung adenocarcinoma arose months after the onset of frequent thrombosis in a healthy person. So recommended to consider the risk of developing cancer in patients with recurrent thrombosis.

References

Saeger W, Genzkow M. Venous thromboses and pulmonary embolisms in post-mortem series: probable causes by correlations of clinical data and basic diseases. Pathology-Research and Practice 1994; 190(4): 394-9. https://doi.org/10.1016/S0344-0338(11)80413-9

Heit JA, Cohen AT, Anderson FA. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Am Soc Hematology 2005. https://doi.org/10.1001/archinte.162.11.1245

Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Archives of Internal Medicine 2002; 162(11): 1245-8.

Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Annals of Oncology 2005; 16(5): 696-701. https://doi.org/10.1093/annonc/mdi165

Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Archives of Internal Medicine 2006; 166(4): 458-64. https://doi.org/10.1001/archinte.166.4.458

Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62(1): 14-31.

Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer investigation 2009; 27(sup1): 63-74.

Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, Le Maître A, et al. Venous thromboembolism and nonsmall cell lung cancer. Cancer 2009; 115(23): 5516-25. https://doi.org/10.1002/cncr.24596

Tafur AJ, Kalsi H, Wysokinski WE, McBane RD, Ashrani AA, Marks RS, et al. editors. The association of active cancer with venous thromboembolism location: a population-based study. Mayo Clinic Proceedings 2011; Elsevier.

Blom J, Vanderschoot J, Oostindier M, Osanto S, Van Der Meer F, Rosendaal F. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. Journal of Thrombosis and Haemostasis 2006; 4(3): 529-35. https://doi.org/10.1111/j.1538-7836.2006.01804.x

Corrales-Rodriguez L, Blais N. Lung cancer associated venous thromboembolic disease: a comprehensive review. Lung Cancer 2012; 75(1): 1-8. https://doi.org/10.1016/j.lungcan.2011.07.004

Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Archives of Internal Medicine 2004; 164(15): 1653-61. https://doi.org/10.1001/archinte.164.15.1653

SØrensen HT, MellemkjÆr L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. New England Journal of Medicine 2000; 343(25): 1846-50. https://doi.org/10.1056/NEJM200012213432504

Prandoni P, Bernardi E, Marchiori A, Lensing AW, Prins MH, Villalta S, et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ 2004; 329(7464): 484-5. https://doi.org/10.1136/bmj.38167.684444.3A

Tagalakis V, Levi D, Agulnik JS, Cohen V, Kasymjanova G, Small D. High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. Journal of Thoracic Oncology 2007; 2(8): 729-34. https://doi.org/10.1097/JTO.0b013e31811ea275

Coleman R, MacCallum P. Treatment and secondary prevention of venous thromboembolism in cancer. British Journal of Cancer 2010; 102: S17-S23.

Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107(23 suppl 1): I-9-I-16.

Varki A. Trousseau9s syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110(6): 1723-9. https://doi.org/10.1182/blood-2006-10-053736

Downloads

Published

2018-08-10

How to Cite

Ali Sharifpour, Siavash Abedi, Masoud Aliyali, Sepideh Safa Navai, Ali Davoodi, & Seyyed Abbas Hashemi. (2018). Incidence of Lung Adenocarcinoma following Recurrent Deep Vein Thrombosis: A Case Presentation . Journal of Analytical Oncology, 7(2), 29–31. https://doi.org/10.6000/1927-7229.2018.07.02.3

Issue

Section

Articles

Similar Articles

You may also start an advanced similarity search for this article.